Drugs in the Pipeline
Phase 3 Study of Masitinib for the Treatment of Asthma
AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma.
Your search for oral corticosteroids returned 132 results
AES 2017
Effectiveness of Infantile Spasm Treatments Compared
Results found that infants with an unknown epilepsy etiology, a normal MRI, an EEG displaying hypsarrhythmia, or those already receiving an AED were more likely to be administered ACTH.
Drugs in the Pipeline
Rituxan Granted Priority Review for Rare Autoimmune Disease
The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering.
News
Factors Associated With Successful Biologics Tapering in RA
There were also significant differences between the groups in concomitant oral corticosteroid use (43.1 vs. 34.8% in the stable treatment and DT groups, respectively) and CRP level (1.9±2.5 vs. 1.1±1.3 respectively).
News
PANS/PANDAS Treatment Guidelines Released
"Immunomodulatory therapy should be considered early, because NSAIDs or a short course of oral corticosteroids may be sufficient for symptom remission in recent-onset cases, whereas those with long-standing symptoms often require more intensive and prolonged immunotherapeutic interventions," the authors write.
News
Corticosteroid Exposure Affects Bone Health in Asthma Patients
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures
News
Early Treatment Key for Managing Nasal Hemangiomas
General consensus supporting early multimodality treatment for infantile hemangiomas of the nose
News
RA Drug Linked to Severe Skin Reaction in Patient with Adult-Onset Still Disease
Diffuse, persistent, pruritic maculopapular rash developed 10 days after tocilizumab treatment
Drugs in the Pipeline
Phase 3 Study of ACZ885 for Children with Systemic Juvenile Idiopathic Arthritis
Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).
News
Respiratory Pathogens May Up Treatment Failure Risk in Asthma
There was a correlation for non-rhinovirus pathogens with increased absolute risk of treatment failure by 13.1%; specifically, by 8.8, 24.9, and 34.1% for respiratory syncytial virus, influenza, and parainfluenza, respectively.
